CMR-316

N/A

Report date: 2024/11/20 16:59:31
NMEFirst In Class

Base Information

Drug NameCMR-316
Drug Alias NameCMR316CMR-316
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDipeptidyl peptidase IV inhibitors
TargetsDipeptidyl peptidase IV
Therapy Area/IndicationsRespiratory Distress Syndrome, AdultIdiopathic Pulmonary FibrosisPulmonary Disease, Chronic Obstructive
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermany
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe Calibr-Skaggs Institute for Innovative Medicines
China Registration ClassN/A

Develop Information

Active CompaniesThe Calibr-Skaggs Institute for Innovative MedicinesCalifornia Institute For Biomedical Research +[3] 
Inactive CompaniesN/A
Active IndicationsRespiratory Distress Syndrome, AdultIdiopathic Pulmonary FibrosisPulmonary Disease, Chronic Obstructive
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A